<DOC>
	<DOCNO>NCT02732886</DOCNO>
	<brief_summary>This study compare efficacy safety Medifoam® Betafoam® , new dress contains povidone-iodine , patient diabetes foot ulcer . 70 patient ( 35 arm ) target enrolled study . The study conduct 57 day .</brief_summary>
	<brief_title>Betafoam Diabetes Mellitus Foot Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Povidone-Iodine</mesh_term>
	<mesh_term>Povidone</mesh_term>
	<criteria>Adult age ≥19 year time inform consent Foot ulcer related diabetes mellitus : Present Type I II diabetes mellitus HbA1c &lt; 10 % , serum creatinine ≤ 200 μmol/l Wagner grade III ( Partial full thickness involve bone , tendon , capsule ( probe tendon capsule ) Post debridement ulcer bed size ≥ 1*1cm2 No clinical sign infection &amp; necrosis Site anywhere ankle No vascular abnormality foot palpation ( i.e . dorsalis pedis examine physician characterized present absent ) Pregnant &amp; lactating female Known allergy dress product include povidone iodine Known hyperthyroidism acute thyroid disease Subject clinical infection administer antibiotic continuously enrolment Subject condition ( ) seriously compromise patient 's ability complete study . Subject participate interventional study utilizing investigational drug within previous 30 day Subjects know immunesuppressed state ; undergo chemotherapy endstage renal disease require haemodialysis kidney transplant surgery previously immunosuppressant specifically Subjects require skin graft per physician 's discretion Vulnerable subject define Good Clinical Practice guideline .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>foam dress</keyword>
</DOC>